Identification of Networks of Co-Occurring, Tumor-Related DNA Copy Number Changes Using a Genome-Wide Scoring Approach

Tumorigenesis is a multi-step process in which normal cells transform into malignant tumors following the accumulation of genetic mutations that enable them to evade the growth control checkpoints that would normally suppress their growth or result in apoptosis. It is therefore important to identify those combinations of mutations that collaborate in cancer development and progression. DNA copy number alterations (CNAs) are one of the ways in which cancer genes are deregulated in tumor cells. We hypothesized that synergistic interactions between cancer genes might be identified by looking for regions of co-occurring gain and/or loss. To this end we developed a scoring framework to separate truly co-occurring aberrations from passenger mutations and dominant single signals present in the data. The resulting regions of high co-occurrence can be investigated for between-region functional interactions. Analysis of high-resolution DNA copy number data from a panel of 95 hematological tumor cell lines correctly identified co-occurring recombinations at the T-cell receptor and immunoglobulin loci in T- and B-cell malignancies, respectively, showing that we can recover truly co-occurring genomic alterations. In addition, our analysis revealed networks of co-occurring genomic losses and gains that are enriched for cancer genes. These networks are also highly enriched for functional relationships between genes. We further examine sub-networks of these networks, core networks, which contain many known cancer genes. The core network for co-occurring DNA losses we find seems to be independent of the canonical cancer genes within the network. Our findings suggest that large-scale, low-intensity copy number alterations may be an important feature of cancer development or maintenance by affecting gene dosage of a large interconnected network of functionally related genes.

[1]  Chris Sander,et al.  An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors , 2009, Oncogene.

[2]  Thorsten Heinzel,et al.  Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.

[3]  P S Gaynon,et al.  Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia , 2000, Cancer.

[4]  A. Berns,et al.  Haplo-insufficiency? Let me count the ways. , 2001, Genes & development.

[5]  M. Leid,et al.  Identification of Nuclear Receptor Corepressor as a Peroxisome Proliferator-activated Receptor α Interacting Protein* , 1999, The Journal of Biological Chemistry.

[6]  Marcel J. T. Reinders,et al.  Co-occurrence analysis of insertional mutagenesis data reveals cooperating oncogenes , 2007, ISMB/ECCB.

[7]  Amit Verma,et al.  AML1-ETO Decreases ETO-2 (MTG16) Interactions with Nuclear Receptor Corepressor, an Effect That Impairs Granulocyte Differentiation , 2004, Cancer Research.

[8]  D. Pinkel,et al.  Array comparative genomic hybridization and its applications in cancer , 2005, Nature Genetics.

[9]  Li Zhao,et al.  Nuclear Receptor Corepressor Is a Novel Regulator of Phosphatidylinositol 3-Kinase Signaling , 2007, Molecular and Cellular Biology.

[10]  Gouri Nanjangud,et al.  Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. , 2006, Blood.

[11]  M. Nowak,et al.  Dynamics of cancer progression , 2004, Nature Reviews Cancer.

[12]  Göran Roos,et al.  Chromosomal Imbalances in Diffuse Large B-Cell Lymphoma Detected by Comparative Genomic Hybridization , 2002, Modern Pathology.

[13]  M. Fiegl,et al.  Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. , 1998, Blood.

[14]  P S Gaynon,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Association of Chromosome Arm 9p Abnormalities With Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group , 2016 .

[15]  O. Sieber,et al.  Genomic instability — the engine of tumorigenesis? , 2003, Nature Reviews Cancer.

[16]  A Benner,et al.  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.

[17]  L. Bullinger,et al.  Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course , 2002, Leukemia.

[18]  Lawrence S. Hon,et al.  High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors , 2009, BMC Medical Genomics.

[19]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[20]  Béatrice Desvergne,et al.  Peroxisome-proliferator-activated receptors and cancers: complex stories , 2004, Nature Reviews Cancer.

[21]  O. Rath,et al.  MAP kinase signalling pathways in cancer , 2007, Oncogene.

[22]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[23]  G. Ehninger,et al.  The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia , 2009, Leukemia.

[24]  Takeshi Suzuki,et al.  Tumor suppressor gene identification using retroviral insertional mutagenesis in Blm‐deficient mice , 2006, The EMBO journal.

[25]  A. Jetten,et al.  Characterization of the Repressor Function of the Nuclear Orphan Receptor Retinoid Receptor-related Testis-associated Receptor/Germ Cell Nuclear Factor* , 2000, The Journal of Biological Chemistry.

[26]  Christian von Mering,et al.  STRING 8—a global view on proteins and their functional interactions in 630 organisms , 2008, Nucleic Acids Res..

[27]  Brian T Chait,et al.  The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. , 2002, Molecular cell.

[28]  T. Hubbard,et al.  Large-Scale Mutagenesis in p19ARF- and p53-Deficient Mice Identifies Cancer Genes and Their Collaborative Networks , 2008, Cell.

[29]  Jun Qin,et al.  Purification and functional characterization of the human N‐CoR complex: the roles of HDAC3, TBL1 and TBLR1 , 2003, The EMBO journal.

[30]  F. Ross,et al.  Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization , 2007, Oncogene.

[31]  Martin A. Nowak,et al.  The significance of unstable chromosomes in colorectal cancer , 2003, Nature Reviews Cancer.

[32]  P Meltzer,et al.  Transgenic Targeting of a Dominant Negative Corepressor to Liver Blocks Basal Repression by Thyroid Hormone Receptor and Increases Cell Proliferation* , 2001, The Journal of Biological Chemistry.

[33]  F Menestrina,et al.  Insights into the multistep transformation process of lymphomas: IgH-associated translocations and tumor suppressor gene mutations in clonally related composite Hodgkin's and non-Hodgkin's lymphomas , 2005, Leukemia.

[34]  S. Gabriel,et al.  High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.

[35]  J. Stockman,et al.  A Network Model of a Cooperative Genetic Landscape in Brain Tumors , 2011 .

[36]  J. Downing,et al.  Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions , 2009, Leukemia.

[37]  Kristen Jepsen,et al.  Combinatorial Roles of the Nuclear Receptor Corepressor in Transcription and Development , 2000, Cell.